抗原|天津九安医疗电子股份有限公司 关于子公司收到iHealth新冠抗原家用自测OTC试剂盒 针对Omicron变异病毒测试性能实验报告的公告( 二 )
The FDA continues to authorize the use of these tests as directed in the authorized labeling and individuals should continue to use them in accordance with the instructions included with the tests. Antigen tests are generally less sensitive and less likely to pick up very early infections compared to molecular tests. In following the FDA's long-standing rapid test recommendations, if a person tests negative with an antigen test but is suspected of having COVID-19, such as experiencing symptoms or have a high likelihood of infection due to exposure, follow-up molecular testing is important for determining a COVID-19 infection. If a person tests positive with an antigen test, they should self-isolate and seek follow-up care with a health care provider to determine the next steps.
FDA官方网站就上述内容的发表链接如下：
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-
cov-2-viral-mutations-impact-covid-19-tests#omicronvariantimpact
特此公告 。
天津九安医疗电子股份有限公司
董事会
2022年1月7日
推荐阅读
- 大餐|把温暖“爱心餐”送到防疫一线 美团助力天津抗疫
- 时间|天津战“疫”：逆境中的光芒
- 来源|天津战“疫”：逆境中的光芒
- 天津|“猎鹰号”气膜实验室投用 “人机配合”每日最多检测80万人份（图）
- 守护|天津移动公司：全力守护城市“红色通信线”
- 平台|天津生态城发布全球首款无人驾驶网格车，可无安全员上路行驶
- 天津|清华大学天津电子信息研究院宇航与装备科技中心揭牌
- 网络|天津联通双千兆升级 助力津城智慧生活
- 公告|九安医疗：iHelath新冠抗原家用自测OTC试剂盒针检测出Omicron活性病毒样本
- 抗原|《科学》杂志：单克隆抗体治疗新冠肺炎大有可为